Serum marker predicts cardiovascular events in diabetes

Serum marker predicts cardiovascular events in diabetes

(HealthDay)—Elevated levels of polyclonal serum immunoglobulin combined free light chains (cFLCs) may indicate adverse cardiovascular disease (CVD) outcomes in patients with type 2 diabetes, according to research published online April 17 in Diabetes Care.

Srikanth Bellary, M.B.B.S., of Aston University in Birmingham, U.K., and colleagues conducted a of 352 South Asian patients with type 2 diabetes to assess the association between cFLCs and cardiovascular disease events.

The researchers found that, among patients with type 2 diabetes who had CVD events during two years of follow-up, cFLC levels were elevated in 8 percent (50.7 versus 42.8 mg/L; P = 0.004). According to , elevated cFLC level (greater than 57.2 mg/L) was associated with adverse CVD outcomes (odds ratio, 3.3; 95 percent confidence interval, 1.3 to 8.2; P = 0.012). This association remained significant after adjustment for age, albumin-to-creatinine ratio, diabetes duration, or treatment.

"cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation," the authors write.

The United Kingdom Asian Diabetes Study and several study authors received funding from pharmaceutical companies.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Genetic predisposition to diabetes ups risk of CVD

Oct 23, 2012

(HealthDay)—For patients with type 2 diabetes (T2D), having a genetic predisposition towards the disease is associated with an increased risk of cardiovascular disease (CVD), according to a study published ...

Interarm BP difference may up cardiac risk in diabetes

Apr 03, 2014

(HealthDay)—Interarm differences in systolic blood pressure (BP) in patients with diabetes may be associated with an increased risk of cardiovascular morbidity and mortality, according to research published ...

Omega-3 fatty acids, xanthophylls don't cut CVD risk

Mar 21, 2014

(HealthDay)—Dietary supplementation with ω-3 polyunsaturated fatty acids or macular xanthophylls do not seem to reduce the risk of cardiovascular disease (CVD) in older adults with age-related macular ...

Recommended for you

Progress in diabetes drug delivery

Jan 22, 2015

A drug therapy for diabetes treatment is being developed by an international research team led by WA scientists, which combines an existing anti-diabetic drug with bile acids to improve the drug's delivery ...

Roux-en-Y surgery can reverse insulin treatment in T2DM

Jan 21, 2015

(HealthDay)—Roux-en-Y gastric bypass surgery (RYGB) strongly predicts insulin cessation after surgery in insulin-treated type 2 diabetes (I-T2D) patients, independent of weight loss, according to a study ...

Unexpected turn in diabetes research

Jan 20, 2015

Years of diabetes research carried out on mice whose DNA had been altered with a human growth hormone gene is now ripe for reinterpretation after a new study by researchers at KU Leuven confirms that the gene had an unintended ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.